For the seventh year, a wonderful drug for the treatment of diabetes appeared on the market, the use of which does not exacerbate the existing ailments of the cardiovascular system, kidneys and liver, the diabetics said. "Trazenta", which is based on the blocker of the enzyme dipeptidyl peptidase-4 linagliptin, refers to hypoclycemic agents. The pharmacological effect of the drug is aimed at reducing the synthesis of the hormonal substance glucagon, as well as at increasing the production of insulin. This class of drugs is currently recognized as one of the most promising for controlling a dangerous ailment - the second type of diabetes.
What is diabetes?
This is a pathology of the endocrine system, as a result of which the concentration of glucose in the blood of an individual increases, since the body loses the ability to absorb insulin. The consequences of this ailment are very serious - metabolic processes fail, vessels, organs and systems are affected. One of the most dangerous and insidious is diabetes of the second type. This disease is called a real threat to humanity.
Among the causes of mortality over the past two decades, it has come first. The main provocative factor in the development of the disease is considered a failure of the immune system. Antibodies are produced in the body that have a destructive effect on pancreatic cells. As a result, glucose in large quantities freely circulates in the blood, having a negative effect on organs and systems. As a result of the imbalance, the body uses fats as an energy source, which leads to increased formation of ketone bodies, which are toxic substances. As a result of this, all types of metabolic processes occurring in the body are disrupted.
Therefore, it is especially important when finding an ailment to choose the right therapy and apply high-quality drugs, for example, “Trazhentu”, reviews of doctors and patients about which can be found below. The danger of diabetes is that for a long period it may not give clinical manifestations, and the detection of overestimated sugar values is detected by chance at the next preventive examination.
The consequences of diabetes
Scientists around the world are constantly conducting research aimed at identifying new formulas for creating a medicine that can defeat a terrible ailment. In 2012, a unique drug was registered in our country, which practically does not cause side effects and is well tolerated by patients. In addition, it is allowed to accept individuals with renal and hepatic insufficiency - as it is written in the reviews of "Trazhent".
Serious danger is the following complications of diabetes:
- decrease in visual acuity up to its complete loss;
- failure in the functioning of the kidneys;
- vascular and heart diseases - myocardial infarction, atherosclerosis, ischemic heart disease;
- foot diseases - purulent-necrotic processes, ulcerative lesions;
- the appearance of ulcers on the dermis;
- skin lesion with fungus;
- neuropathy, which is manifested by convulsions, peeling and a decrease in the sensitivity of the skin;
- coma;
- violation of the functions of the lower extremities.
"Trazhenta": description, composition
A medication is produced in tablet dosage form. Round biconvex tablets with beveled edges have a light red shell. On one side there is a symbol of the manufacturer, presented in the form of an engraving, on the other - the alphanumeric designation D5.
The active ingredient is linagliptin, due to its high effectiveness for one dose, five milligrams is enough. This component, increasing insulin production, reduces glucagon synthesis. The effect occurs one hundred and twenty minutes after administration - it is after this time that its maximum concentration in the blood is observed. Excipients necessary for the formation of tablets:
- magnesium stearate;
- pregelatinized and corn starch;
- mannitol - diuretic;
- copovidone is an absorbent.
The shell consists of hypromellose, talc, red dye (iron oxide), macrogol, titanium dioxide.
Features of the drug
According to doctors, “Trazhenta” in clinical practice has proven its effectiveness in the treatment of the second type of diabetes mellitus in fifty countries of the world, including Russia. Studies were conducted in twenty-two countries in which thousands of patients with the second type of diabetes took part in testing the drug.
Due to the fact that the medicine is excreted from the body of the individual through the gastrointestinal tract, and not through the kidneys, with a deterioration in their work, dosage adjustment is not required. This is one of the significant differences between Trazhenty and other antidiabetic drugs. The following advantage is as follows: the patient does not have hypoglycemia when taking tablets, both in conjunction with Metformin, and with monotherapy.
About the manufacturers of the drug
The production of Trazhenta tablets, reviews of which are freely available, is carried out by two pharmaceutical companies.
- “Eli Lilly” - for 85 years has been one of the world leaders in the field of innovative decisions aimed at supporting patients with a diagnosis of diabetes. The company is constantly expanding its range using the latest research.
- “Beringer Ingelheim” - leads its history since 1885. He is engaged in research, development, production, as well as the sale of medicines. This company is one of the twenty world leaders in the field of pharmaceuticals.
In early 2011, both companies signed an agreement on cooperation in the field of diabetes, thanks to which significant progress has been achieved in the treatment of insidious illness. The purpose of the interaction is to study a new combination of four chemicals that are part of drugs designed to eliminate the symptoms of the disease.
Indications for use
According to reviews and instructions for use, "Trazhenta" is recommended for use for the treatment of the second type of diabetes mellitus both with monotherapy and in conjunction with other tablet hypoglycemic agents, as well as insulin preparations. In the first case, it is prescribed for:
- contraindications to taking Metformin or kidney damage;
- inadequate glycemic control against the background of physical education and a special diet.
With the ineffectiveness of monotherapy with the following medicines, as well as with the help of diet and exercise, complex treatment is indicated.
- With sulfonylurea derivatives, Metformin, thiazolidinedione.
- With insulin or Metformin, pioglitazone, sulfonylureas, and insulin.
- With Metformin and sulfonylurea derivatives.
Contraindications
According to reviews and instructions, “Trazhent” is forbidden to take while the baby is waiting, as well as during natural feeding. In preclinical studies, it was found that the active substance (linagliptin) and its metabolites pass into breast milk. Therefore, it is impossible to exclude a negative effect on the fetus and the crumbs that are on breastfeeding. If it is impossible to cancel the drug and replace it with a similar one, the doctors insist on the transition from natural to artificial feeding.
Tablets are also contraindicated in the following conditions:
- age up to eighteen years;
- diabetic ketoacidosis;
- type 1 diabetes mellitus;
- individual intolerance to the ingredients that make up the "Trazenti".
In the reviews of doctors, as well as in the instructions for the use of this drug, there is information that it should be used with caution for persons over eighty years old while taking it with insulin and (or) sulfonylurea-based drugs. Studies on the effect of the drug on the ability to drive mechanisms and vehicles have not been conducted. However, due to the possible occurrence of hypoglycemia, especially when receiving combination therapy, caution should be exercised. If acute pancreatitis is detected, the drug should be discontinued. In this case, the doctor will choose a different therapy.
special instructions
It is important to remember that for the treatment of ketoacidosis of type 1 diabetes mellitus, the use of Trazenti is prohibited. In diabetic reviews, such a warning is quite common. In addition, it is noted that the risk of pathologies of the cardiovascular system does not increase. Individuals with a malfunction of the liver and kidneys can safely take the drug in the usual dose, its adjustment is not required.
In the age category from seventy to eighty years, the use of linagliptin showed good results. A significant decrease was observed:
- glycosylated hemoglobin;
- plasma sugar levels on an empty stomach.
Taking the medication by people who have crossed the eighty-year mark should be carried out with extreme caution, since the clinical experience with this group is very limited.
The incidence of hypoglycemia is minimal when taking only one "Trazenta". Patient reviews also confirm this fact. In addition, in their comments, they note that, in combination with other medicines for diabetes, the development of glycemia is negligible. In these cases, if necessary, the doctor can reduce the dose of insulin or sulfonylurea derivatives. Reception "Trazhenty" does not increase the risk of heart attack or stroke, which is important when taking it at an older age.
Adverse reactions
Many medicines used to treat diabetes can lead to a pathological condition in which the level of glucose in the blood decreases sharply, which poses a serious danger to the individual. "Trazhenta", in the reviews of which it is said that taking it does not cause hypoglycemia, is an exception to the rule. This is considered an important advantage over other classes of hypoglycemic agents. Of the adverse reactions that can occur during the period of therapy "Trazentoy", the following:
- pancreatitis
- coughing attacks;
- nasopharyngitis;
- hypersensitivity;
- an increase in plasma amylase;
- rash;
- and others.
In case of an overdose, routine measures are indicated aimed at removing an unabsorbed drug from the digestive tract and symptomatic treatment.
"Trazhenta": reviews of diabetics and medical practitioners
The high effectiveness of the drug has been repeatedly confirmed by medical practice and international studies. Endocrinologists in their comments recommend using it in combination treatment or as a first-line therapy. If the individual has a tendency to hypoglycemia, which provokes improper nutrition and physical activity, it is advisable to assign “Trazent” instead of sulfonylurea derivatives. It is not always possible to evaluate the effectiveness of the drug if it is taken in combination therapy, but in general the result is positive, which is also noted by patients. There are reviews about the drug "Trazhenta" when it was recommended for obesity and insulin resistance.
The advantage of these antidiabetic pills is that they do not contribute to weight gain, do not provoke the development of hypoglycemia, and also do not exacerbate kidney problems. Trazhenta has enhanced safety, which is especially important for diabetics. Therefore, there are a fairly large number of positive reviews about this unique tool. Among the minuses note the high cost and individual intolerance.
Analog drugs "Trazhenty"
The reviews left by patients taking this medication are mostly positive. However, for some individuals, due to hypersensitivity or intolerance, doctors recommend similar remedies. These include:
- “Sitagliptin”, “Januvia” - patients take this remedy as an addition to exercise, diet, to improve control over glycemic state; in addition, the drug is actively used in combination therapy;
- "Alogliptin", "Vipidia" - most often this medication is recommended in the absence of the effect of dietary nutrition, physical activity and monotherapy;
- “Saksagliptin” - is produced under the trade name “Onglisa” for the treatment of the second type of diabetes mellitus, it is used both in monotherapy and with other tablet medicines and inulin.
Selection of an analogue is carried out only by the treating endocrinologist, self-medication change is prohibited.
Patients with kidney failure
“Excellent highly effective medicine” - such words usually start rave reviews about “Trazhent”. Serious concern when taking antidiabetic drugs has always been experienced by individuals with a malfunction of the kidneys, especially those undergoing hemodialysis. With the advent of this drug in the pharmacy network, patients with kidney pathologies praised it, despite the high cost.
Due to the unique pharmacological action, glucose values are significantly reduced when taking the medicine only once a day at a therapeutic dose of five milligrams. And it does not matter the time of taking the tablets. The drug is rapidly absorbed after penetration into the digestive tract, the maximum concentration is observed after one and a half or two hours after administration. It is excreted in feces, i.e., the kidneys and liver do not participate in this process.
Conclusion
According to diabetic reviews, Trazhent can be taken at any convenient time, regardless of nutrition and only once a day, which is considered a huge plus. The only thing to remember: you can not take a double dose in one day. In combination therapy, the dosage of "Trazhenty" does not change. In addition, its adjustment is not required in case of problems with the kidneys. The tablets are well tolerated, adverse reactions are quite rare. "Trazhenta", reviews of which are extremely enthusiastic, contains a unique active substance with high efficiency. It is also important that the medicine is included in the list of drugs that are omitted in pharmacies for free prescriptions.